DNX Corp., Isis Pharmaceuticals regulatory update

DNXX received notice of allowance for a U.S. patent covering non-pancreatic phospholipase A2 (PLA2) transgenic mice and rats and their use in developing compounds to inhibit PLA2. PLA2 is an enzyme t...